Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.55 |
| ▸ | MAOB | P27338 | 3/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | AHR | P35869 | 1/20 | 0.42 |
| ▸ | CHAT | P28329 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL144445 | 1.00 | HTR2A (0.55) | HTR2AMAOBRELACYP19A1MAOA | |
| SCHEMBL7296999 | 1.00 | HTR2A (0.55) | HTR2AMAOBRELACYP19A1MAOA | |
| SCHEMBL19586405 | 1.00 | HTR2A (0.55) | HTR2AMAOBRELACYP19A1MAOA | |
| SCHEMBL28993553 | 0.80 | MAOB (0.50) | HTR2AMAOBCYP19A1MAOACYP1A2 | |
| SCHEMBL7568407 | 0.80 | CHAT (0.50) | HTR2AMAOBRELACYP19A1MAOA | |
| SCHEMBL6844031 | 0.80 | MAOB (0.50) | HTR2AMAOBRELACYP1A2AHR | |
| SCHEMBL7568402 | 0.80 | CHAT (0.50) | HTR2AMAOBRELACYP19A1MAOA | |
| SCHEMBL9960125 | 0.80 | MAOB (0.50) | HTR2AMAOBCYP19A1MAOACYP1A2 | |
| SCHEMBL56244 | 0.80 | MAOB (0.50) | HTR2AMAOBRELACYP1A2AHR | |
| SCHEMBL8784150 | 0.78 | TLR4 (0.51) | MAOBCYP1A2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017096315-A1 | TRIAZOLE DAGL(α) INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-06-08 | — | — | WO | disclosed |
| US-8883824-B2 | 3-(4-aminophenyl)-2-furancarboxylic acid derivative and pharmaceutically acceptable salt thereof | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2014-11-11 | — | — | US | disclosed |
| EP-2686336-A1 | N-CARBOXYALKYL-AURISTATINS AND USE THEREOF | Seattle Genetics, Inc. (US) | 2014-01-22 | — | — | EP | disclosed |
| EP-2595483-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | Merck Sharp & Dohme Corp. (US) | 2013-05-29 | — | — | EP | disclosed |
| US-8399594-B2 | Blocked-isocyanate silicone resins | DOW CORNING CORPORATION (US) | 2013-03-19 | — | — | US | disclosed |
| WO-2012123423-A1 | N-CARBOXYALKYL-AURISTATINS AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-09-20 | — | — | WO | disclosed |
| EP-2431362-A1 | 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2012-03-21 | — | — | EP | disclosed |
| US-20120059012-A1 | 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| WO-2012012314-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-01-26 | — | — | WO | disclosed |
| CN-101611098-B | Blocked isocyanate silicone resins | DOW CORNING INC | 2011-10-26 | — | — | CN | disclosed |
| US-20100093902-A1 | Blocked-Isocyanate Silicone Resins | DOW CORNING CORPORATION | 2010-04-15 | — | — | US | disclosed |
| CN-101611098-A | Blocked isocyanate silicone resins | DOW CORNING CORPORATRION (US) | 2009-12-23 | — | — | CN | disclosed |
| US-20070167587-A1 | Process for producing polymer with functional end | KURARAY CO., LTD. (JP) | 2007-07-19 | — | — | US | disclosed |
| EP-1721912-A1 | PROCESS FOR PRODUCING POLYMER WITH FUNCTIONAL END | KURARAY CO., LTD. (JP) | 2006-11-15 | — | — | EP | disclosed |
| EP-1340081-A4 | COMPOSITION AND METHODS FOR SYNTHESIS OF NOVEL TRACERS FOR DETECTING AMPHETAMINE AND METHAMPHETAMINE IN SAMPLES | LIFEPOINT INC (US) | 2005-08-03 | — | — | EP | disclosed |
| EP-1340081-A2 | COMPOSITION AND METHODS FOR SYNTHESIS OF NOVEL TRACERS FOR DETECTING AMPHETAMINE AND METHAMPHETAMINE IN SAMPLES | Lifepoint, Inc. (US) | 2003-09-03 | — | — | EP | disclosed |
| US-6472228-B2 | SYNTHETIC TRACER FOR USE IN DRUG SCREENING | LIFEPOINT, INC. | 2002-10-29 | — | — | US | disclosed |
| WO-2002057739-A2 | COMPOSITION AND METHODS FOR SYNTHESIS OF NOVEL TRACERS FOR DETECTING AMPHETAMINE AND METHAMPHETAMINE IN SAMPLES | LIFEPOINT, INC. (US) | 2002-07-25 | — | — | WO | disclosed |
| US-20020090661-A1 | Composition and methods for synthesis of novel tracers for detecting amphetamine and methamphetamine in samples | GENERAL CONFERENCE CORPORATION OF SEVENTH-DAY ADVENTISTS | 2002-07-11 | — | — | US | disclosed |
| US-4994569-A | Cholecystokinin antagonists | RHONE-POULENC SANTE (FR) | 1991-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059012-A1 | 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACSL3, SLCO4C1, SLC38A7 | HTR2A 2926/4885MAOB 737/4885RELA 2567/4885 |
| US-20020090661-A1 | Composition and methods for synthesis of novel tracers for detecting amphetamine and methamphetamine in samples | NEFM, OPRM1, TAAR5 | HTR2A 734/4885MAOB 88/4885RELA 4838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.